Fig. 6: LNPIT-PNP and fludarabine phosphate combination therapy has anti-tumor effects validated across various HNSCC preclinical models.
From: Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses
Tumor growth studies in two additional in vivo HNSCC models: a FaDu, human HNSCC xenografts inoculated in immunocompromised NU/J mice (n = 4–5 experimental replicates, mean +/− SD; p12 for group 1 vs 2, p13 for group 1 vs 3, p14 for group 1 vs 4), and (b), MOC1, syngeneic HNSCC murine tumors inoculated in immunocompetent C57BL/6 mice (n = 5–6 experimental replicates, mean +/− SD; p12 for group 1 vs 2, p13 for group 1 vs 3, p14 for group 1 vs 4). Tumor volume was compared to the control groups using a two-way ANOVA with Tukey post-hoc test for multiple comparisons. c An in vitro assay to assess the anti-tumor cell effects of combination therapy in the syngeneic MOC1 murine line, FaDu human tumor cells, and four HNSCC patient-derived xenograft lines (PDX1, PDX2, PDX3, and PDX4). MeP-dR is an analogue of fludarabine phosphate (prodrug), used as a prototype compound for showing PNP activity. MeP is the toxic cleavage product of MeP-dR following PNP treatment and serves as a positive control (n = 3 experimental replicates consisting of wells seeded with the respective cell line). Source data are provided as a Source Data file.
